Whether adagrasib (Krazati) is a targeted drug and its positioning in precision treatment

Adagrasiib (Krazati) is a small molecule targeted drug that mainly affects tumor patients with KRAS G12C mutations. KRAS G12C is one of the common driver gene mutations in non-small cell lung cancer (NSCLC) and other solid tumors. Its mutation will continuously activate the RAS/MAPK signaling pathway, promoting tumor cell proliferation and resistance to apoptosis. Adagrasib covalently binds to the KRAS G12C protein to keep it in an inactive state, thereby inhibiting downstream signaling pathways and achieving precise targeted therapy. Therefore, it is clearly classified as a targeted drug.

In the context of precision medicine, the core value of adagrasib is to provide personalized treatment options for specific gene mutations. KRAS G12CPatients with mutations usually have limited response to traditional chemotherapy or immunotherapy, but adagrasib can directly act on the mutated driver gene and block tumor proliferation signals, thereby significantly improving the efficacy. Its use is based on genetic testing results. Only patients confirmed by testing to carry the KRAS G12C mutation are suitable for treatment. This is also a typical application mode of precision therapy.

Adagrasib is mainly used for KRAS G12C-positive advanced non-small cell lung cancer, especially for patients who are resistant to chemotherapy or immunotherapy or who have relapsed. In addition, some clinical studies are also exploring its application in other KRAS G12C mutation-related solid tumors, such as colorectal cancer, pancreatic cancer, etc. By directly targeting KRAS mutations, adagrasib is positioned as an important choice for second-line and multi-line treatment in precision therapy, providing a new treatment strategy for refractory patients.

As a targeted drug, adagrasib has the advantages of high selectivity, low non-target toxicity, and significant precise efficacy . In the future, its development prospects in precision medicine are broad, and it can be used in combination with immunotherapy or other targeted drugs to further improve efficacy and extend progression-free survival (PFS). At the same time, with the popularization of genetic testing technology, more patients can accurately identify the KRAS G12C mutation, thereby benefiting from the precise targeted treatment of adagrasib.

Reference link:https://www.drugs.com